A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin

Canadian Journal of Gastroenterology

Volumn 23, Issue 10, 2009, Pages 677-683

  Mistry, Nisha ^a   Shapero, Jonathan ^a   Crawford, Richard I ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cutaneous; Drug; Eruption; Interferon; Ribavirin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CEPHALOSPORIN DERIVATIVE; FUROSEMIDE; GLUCOCORTICOID; GOLD; HEPARIN; IBUPROFEN; INTERFERON; ISONIAZID; LITHIUM; LOW MOLECULAR WEIGHT HEPARIN; MACROLIDE; NAPROXEN; OPIATE; PENICILLAMINE; PENICILLIN G; PHENYTOIN; RIBAVIRIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ACNE; ALOPECIA; BULLOUS SKIN DISEASE; DRUG ERUPTION; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ECZEMA; HEPATITIS B; HEPATITIS C; HOSPITAL CARE; HUMAN; INJECTION SITE REACTION; LICHENOID; LUPUS VULGARIS; MORBIDITY; MORTALITY; PIGMENT DISORDER; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PSORIASIS; PUSTULE; RASH; REVIEW; SARCOIDOSIS; SKIN MANIFESTATION; SKIN NECROSIS; URTICARIA;

ALOPECIA; ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; ECZEMA; HEPATITIS C; HUMANS; INTERFERONS; PSORIASIS; RIBAVIRIN; SARCOIDOSIS;

EID: 70449717481     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/651952     Document Type: Review

References (101)

1. Vervloet D, Durham S. ABC of allergies: Adverse reactions to drugs. BMJ 1998;316:1511-1514 (Pubitemid 28224967)
2. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986;256:3358-3363
3. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5:309-316
4. Schwaber MJ, Zlotogorski A. Dermatologic manifestations of hepatitis C infection. Int J Dermatol 1997;36:251-254
5. Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005;23:171-181 (Pubitemid 40410720)
6. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Eng J Med 1994;331:1272-1285 (Pubitemid 24333193)
7. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens- Johnson syndrome: Pathogenesis, diagnosis, and management. Ann Med 2008;40:129-138 (Pubitemid 351640646)
8. Vazquez-Lopez F, Manjon-Haces JA, Perez-Alvarez R, Perez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: The value of an interdisciplinary assessment. Brit J Dermatol 2004;150:1046-1047 (Pubitemid 38903555)
9. Kerl K, Negro F, Lubbe J. Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. Brit J Dermatol 2003;149:656. (Pubitemid 37281607)
10. Sookoian S, Neglia V, Castano G, Frider B, Kien MC, Chohuela E. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999;135:1000-1001 (Pubitemid 29382455)
11. Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roe E, Alomar A. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol 2005;53:62-66 (Pubitemid 40826695)
12. Fortuno Y, Marcoval J, Gallego I, Moreno A, Arbizu T, Peyri J. Reacciones cutaneas por interferon beta en una serie de 92 pacientes conesclerosismultiple. MedClin (Barc) 1999;113:447-448 (Pubitemid 29513095)
13. Sasseville D, Ghamdi WA, Khenaizan SA. Interferon-induced cutaneous necrosis. J Cutan Med Surg 1999;3:320-323
14. Gallina K, Brodell RT, Naffah F, Nedorost S. Local blistering reaction complicating subcutaneous injection of pegylated interferon in a patient with hepatitis C. J Drug Dermatol 2003;2:63-67
15. Sanders S, Busam K, Tahan SR, Johnson RA, Sachs D. Granulomatous and suppurative dermatitis at interferon alfa injection sites: Report of 2 cases. J Am Acad Dermatol 2002;46:611-616
16. Lang AM, Norland AM, Schuneman RL, Tope WD. Localized interferon alfa-2b-induced alopecia. Arch Dermatol 1999;135:1126-1128
17. Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: Report of five cases. J Cutan Pathol 2007;34:18-21. (Pubitemid 350098887)
18. Koontz D, Alshekhlee A. Embolia cutis medicamentosa following interferon beta injection. Mult Scler 2007;13:1203-1204 (Pubitemid 351541427)
19. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986;1:1466-1468
20. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005;15:107-109 (Pubitemid 40434638)
21. Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drug Dermatol 2005;4:221-222
22. Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 2000;76:365-367 (Pubitemid 30335920)
23. Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2007;19:811-815 (Pubitemid 47266713)
24. Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167-169 (Pubitemid 40981076)
25. Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004;21:577-579 (Pubitemid 39363180)
26. Dereure O, Raison-Peyron N, Larrey D, et al. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: A series of 20 patients. Brit J Dermatol 2002;147:1142-1146 (Pubitemid 36963020)
27. Conde-Taboada A, de la Torre C, Feal C, Mayo E, Gonzalez-Sixto B, Cruces MJ. Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection. Brit J Dermatol 2005;153:1070-1072 (Pubitemid 41540785)
28. Girard C, Bessis D, Blatire V, Guilhou JJ, Guillot B. Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection. Brit J Dermatol 2005;152:182-183 (Pubitemid 40193861)
29. Shen Y, Pielop J, Hsu S. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection. Arch Dermatol 2005;141:102-103 (Pubitemid 40144456)
30. Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004;140:215-217 (Pubitemid 38500335)
31. Wright M, Forton D, Main J, et al. UK Mild HCV Trial investigators. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: A multicentre randomized controlled trial. J Viral Hepatitis 2008;12:58-66.
32. Agesta N, Zabala R, Diaz-Perez JL. Alopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology 2002;205:300-301 (Pubitemid 36158545)
33. Radny P, Bauer J, Caroli UM, et al. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma? Dermatology 2004;209:249-250
34. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Euro J Gastroenterol Hepatol 2007;19:817-820 (Pubitemid 47266714)
35. Demirturk N, Aykin N, Demirdal T, Cevik F. Alopecia universalis: A rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006;16:579-580 (Pubitemid 44861836)
36. Taliani G, Biliotti E, Capanni M, Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemotherapy 2005;17:212-214 (Pubitemid 40732882)
37. Kadayifcilar S, Boyacioglu S, Kart H, Gursoy M, Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 1999;13:241-246 (Pubitemid 29210148)
38. Ozdogan M, Gur G, Kadayifcilar S, Boyacioglu S, Ozgur O, Teletar H. An unusual adverse effect of interferon: Hypertrichosis of the eyelashes. J Interf Cytok Res 2000;20:633-634 (Pubitemid 30481715)
39. Dikici B, Bosnak M, Dagli A, Haspolat K. Interferon alpha and hypertrichosis of eyelashes. Pediatr Infect Dis J 2002;21:448-449
40. Goksugur N, Karabay O. Eyelash and eyebrow trichomegaly induced by interferon-alfa 2a. Clin Exp Dermatol 2007;32:583-584 (Pubitemid 47231140)
41. Howaizi M. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005;20:1945-1946 (Pubitemid 43961059)
42. Hernandez-Nunez A, Fernandez-Herrera J, Buceta LR, Garcia-Diez A. Trichomegaly following treatment with interferon alpha-2b. Lancet 2002;359:1107.
43. Misery L. Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin. J Interf Cytok Res 2002;22:881-882 (Pubitemid 35217519)
44. Tinio P, Hadi S, Al-Ghaithi K, Al-Qari H, Rudikoff D. Segmental vitiligo and hair curling after interferon alpha and ribavirin treatment for hepatitis C. Skinmed 2006;5:50-51
45. Kavak A, Akcan Y, Korkmaz U. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin. Dermatology 2005;211:171-172 (Pubitemid 41160261)
46. Ramos-Casals M, Mana J, Nardi N, et al. HISPAMEC Study Group. Sarcoidosis in patients with chronic hepatitis C virus infection: Analysis of 68 cases. Medicine 2005;84:69-80.
47. Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alphaassociated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004;328:173-175 (Pubitemid 39295865)
48. Pelletier F, Manzoni P, Jacoulet P, Humbert P, Aubin F. Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma. Cutis 2007;80:441-445
49. Alonso-Perez A, Ballestero-Diez M, Fraga J, Garcia-Diez A, Fernandez-Herrera J. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma. J Eur Acad Dermatol 2006;20:1328-1329 (Pubitemid 44614638)
50. Toulemonde A, Quereux G, Dreno B. Sarcoidosis granuloma on a tattoo induced by interferon alpha. Ann Dermatol Vener 2004;131:49-51. (Pubitemid 38280163)
51. Werchniak AE, Cheng SX, Dhar AD, Klaus SN. Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin. Clin Exp Dermatol 2004;29:547-548
52. Nawras A, Alsolaiman MM, Mehboob S, Bartholomew C, Maliakkal B. Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. Dig Dis Sci 2002;47:1627-1631 (Pubitemid 34753946)
53. Perez-Gala S, Delgado-Jimenez Y, Goiriz R, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Cutaneous sarcoidosis limited to scars following pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. J Eur Acad Dermatol 2007;21:393-394 (Pubitemid 46243336)
54. Hwang CJ, Gausas RE. Sarcoid-like granulomatous orbital inflammation induced by interferon-alpha treatment. Ophthal Plast Recons 2008;24:311-313
55. Celik G, Sen E, Ulger AF, et al. Sarcoidosis caused by interferon therapy. Respirology 2005;10:535-540
56. Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol 2008;14:166-168
57. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178-181
58. Lodato F, Tame MR, Colecchia A. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006;12:4253-4255 (Pubitemid 44376915)
59. Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K. Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: A case report and review of the literature. Am J Gastroenterol 2000;95:310-312
60. Crispin JC, Diaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus 2005;14:495-496 (Pubitemid 40961327)
61. Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda S. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient. J Clin Neurosci 2007;14:997-1000. (Pubitemid 47333182)
62. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. Plos Med 2006;3:e491.
63. Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol 2003;2:570-573
64. Tai YJ, Tam M. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol 2005;46:154-157
65. Gurguta C, Kauer C, Bergholz U, Formann E, Steindl-Munda P, Ferenci P. Tongue and skin hyperpigmentation during PEGinterferon- alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2006;101:197-198 (Pubitemid 43381730)
66. Willems M, Munte K, Vrolijk JM, et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Brit J Dermatol 2003;149:390-394 (Pubitemid 37100268)
67. Torres HA, Bull L, Arduino RC, Barnett BJ. Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy. Am J Gastroenterol 2007;102:1334-1335 (Pubitemid 46802016)
68. Sood A, Midha V, Bansal M, Goyal A, Sharma N. Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Ind J Gastroenterol 2006;25:324. (Pubitemid 46708845)
69. Tomasiewicz K, Modrzewska R, Semczuk G. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report. Adv Ther 2006;23:139-142
70. Nagao Y, Kawaguchi T, Ide T, Kumashiro R, Sata M. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med 2005;15:237-241
71. Guijarro B, Lopez Sanchez AF, Hernandez Vallejo G. Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. Medicina Oral 2001;6:358-363 (Pubitemid 33070813)
72. Varela P, Areias J, Mota F, Canelhas A, Sanches M. Oral lichen planus induced by interferon-alpha-N1 in a patient with hepatitis C. Int J Dermatol 2000;39:239-240 (Pubitemid 30223896)
73. Armour K, Lowe P. Complicated lichenoid drug eruption. Australas J Dermatol 2005;46:21-24
74. Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol 2003;17:193-195
75. Dominguez MV, Mateu AV, Vieira R, Solano JL, Sintes RN, Salmeron MT. Linear lichen planus and hepatitis C. Dermatol Online J 2006;12:17.
76. Gonzalez-Sixto B, Garcia-Doval I, Conde A, et al. Lichen aureus induced by interferon-alpha plus ribavirin. Acta Derm-Venereol 2007;87:87-88 (Pubitemid 46225402)
77. Scheler M, Proelss J, Brauninger W, Bieber T, Wenzel J. Generalized lichen nitidus with involvement of the palms following interferon alpha treatment. Dermatology 2007;215:236-239 (Pubitemid 47378992)
78. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-279 (Pubitemid 40165370)
79. Antunes I, Azevedo F, Mesquita-Guimaraes J, Resende C, Fernandes N, MacEdo G. Grover's disease secondary to ribavirin. Brit J Dermatol 2000;142:1257-1258
80. Borghi-Scoazec G, Merle P, Scoazec JY, Claudy A, Trepo C. Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C. J Hepatol 2004;40:871-872 (Pubitemid 38507374)
81. Cammarota G, Cuoco L, Cianci R, Pandolfi F, Gasbarrini G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 2000;356:1494-1495
82. Robaeys G, De Bie J, Van Ranst M, Buntinx F. An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment. World J Gastroenterol 2007;13:2379-2380 (Pubitemid 46860742)
83. Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Euro J Gastroenterol Hepatol 2007;19:811-815 (Pubitemid 47266713)
84. Kluger N, Moguelet P, Chaslin-Ferbus D, Khosrotherani K, Aractingi S. Generalized interstitial granuloma annulare induced by pegylated interferon-alpha. Dermatology 2006;213:248-249
85. Tursen U, Kaya TI, Ikizoglu G. Interferon-alpha 2b induced facial erythema in a woman with chronic hepatitis C infection. J Eur Acad Dermatol 2002;16:285-286 (Pubitemid 34785332)
86. Ruiz-Genao DP, Garcia-F-Villalta MJ, Hernandez-Nunez A, et al. Livedo reticularis associated with interferon alpha therapy in two melanoma patients. J Eur Acad Dermatol 2005;19:252-254
87. Von Stebut E, Brauninger W. Development of oil cysts after subcutaneous injection of interferon-alpha and interleukin-2. Brit J Dermatol 2006;155:848-849
88. Dohmen K, Miyamoto Y, Irie K, Takeshita T, Ishibashi H. Manifestation of cutaneous polyarteritis nodosa during interferon therapy for chronic hepatitis C associated with primary biliary cirrhosis. J Gastroenterol 2000;35:789-793 (Pubitemid 30831225)
89. Tahara H, Kojima A, Hirokawa T, et al. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med 2007;46:473-476 (Pubitemid 46629944)
90. Saydam G, Bozkurt D, Sahin F, et al. Acral sclerosis due to interferon-alpha-2b in chronic myelogenous leukemia. Acta Haematol-Basel 2002;107:43-45 (Pubitemid 34701964)
91. Gil M, Chizzolini C, Kaya G, Hauser C. Erythema elevatum et diutinum, multiple sclerosis and interferon beta. Dermatology 2004;209:75-76 (Pubitemid 39179115)
92. Bugatti L, Filosa G, Nicolini M, Filosa A, Verdolini R. Atrophie blanche associated with interferon-alfa adjuvant therapy for melanoma: A cutaneous side effect related to the procoagulant activity of interferon? Dermatology 2002;204:154.
93. Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000;17:64-69
94. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 2004;10:85-86 (Pubitemid 38100532)
95. Benito-Leon J, Borbujo J, Cortes L. Cutaneous mucinoses complicating interferon beta-1b therapy. Eur Neurol 2002;47:123-124 (Pubitemid 34161167)
96. Dimitroulopoulos D, Dourakis SP, Xinopoulos D, Tsamakidis K, Paraskevas E. Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1. J Viral Hepatitis 2004;11:477-478 (Pubitemid 39336232)
97. Adisen E, Dizbay M, Hizel K, Ilter N. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection. Ind J of Dermatol Venereol Leprol 2008;74:60-62
98. Batisse D, Karmochkine M, Jacquot C, Kazatchkine MD, Weiss L. Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 2004;16:701-703 (Pubitemid 38901640)
99. Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol 2003;17:193-195
100. Jensen SL, Holmes R. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy. J Drug Dermatol 2003;2:554-556
101. Bettoli V, Mantovani L, Boccia S, Virgili A. Rosacea fulminans related to pegylated interferon alpha-2b and ribavirin therapy. Acta Derm Venereol 2006;86:258-259 (Pubitemid 43875219)